Pharmacosmos Therapeutics to acquire G1 Therapeutics for $405m.

Pharmacosmos Therapeutics, a pharmaceutical company, agreed to acquire G1 Therapeutics, a clinical-stage company developing small-molecule therapies, for $405m. “G1 and Pharmacosmos have a shared commitment to people living with cancer; the transaction announced today will enable a more rapid uptake of COSELA into the ES-SCLC market to maximize availability for patients who need this important drug. Importantly, this acquisition delivers significant value to G1’s stakeholders by providing better and broader access to this important product for the cancer patients we seek to treat and a significant premium to our shareholders. I am proud of all that the G1 team has accomplished over the years, thankful for their great effort, and excited about what’s possible by the combined Pharmacosmos/G1 team as we meet the needs of more cancer patients," Jack Bailey, G1 Therapeutics CEO.